Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
(9h)
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
(11h)
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
(14h)
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
(15h)
Spruce spins out preclinical endocrinology program into newly formed Adrenyx
(15h)
Zura scraps hidradenitis suppurativa program after phase 2 miss, sinking stock
(16h)
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
(16h)
Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor
(17h)
When China Fits a Global Clinical Development Strategy
(17h)
Kyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drug
(17h)
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
(18h)
Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead
(19h)
Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 test
(21h)
Argenx inks $1.15B Unnatural Products buyout to expand in oral peptides
(22h)
Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
(2d)
Looking Beyond the First Answer Towards Delivering Impact
(3d)
Use Kidney Genetics to Strengthen Clinical Trial Design
(3d)
Chutes & Ladders—Novo's longtime CFO to hang up gloves as Galderma exec steps in
(3d)
There's more than one way to build a biotech
(3d)
Generate CEO sees ‘huge opportunity’ from using Claude to shorten CAR-T cell engines
(3d)
BioPharma Dive
BIO unveils plan for US to remain biotech’s ‘global leader’
(1h)
Bayer wins FDA nod for a new kind of blood thinner
(7h)
Vir hepatitis D drug succeeds in first pivotal study
(13h)
Argenx to buy peptide platform in potentially billion-dollar deal
(13h)
Ramaswamy’s biotech baggage haunted his political run
(14h)
State incentives for commercial-stage life sciences companies
(20h)
Translating Phase II success into Phase III readiness takes more than scale
(20h)
Making the ‘impossible’ executable in life sciences construction
(20h)
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
(3d)
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
(3d)
This week in charts: 3 drug launches Wall Street is watching
(3d)
Medicare will cut billions from 340B, expand site-neutral payments in 2027
(4d)
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
(4d)
Revolution’s Rasonque off to best cancer drug launch ‘in history’
(4d)
T-Therapeutics reloads with a $133M megaround for bispecifics
(4d)
Alethio raises $90M to target rare blood cancers
(5d)
Sanofi stops development of Nurix-partnered immune drug
(5d)
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
(5d)
CVS to split into two companies in stunning strategic about-face
(5d)
Biopharma likely to climb higher after ‘blue wave,’ analysts say
(5d)
Endpoints News
Bayer wins FDA approval for stroke prevention drug Sunharbo
(6h)
How early efforts to build autonomous clinical AI tools are approaching regulation
(9h)
Trump’s drug pricing deals force tough choices on launches
(10h)
FDA orders GLP-1 drugmakers to warn of rare eye disease
(10h)
US government removes WuXi AppTec from Chinese military list
(11h)
Third Rock enters $2B partnership with AI-focused Chinese biotech
(11h)
Heron sells assets to CorMedix for $145M upfront; Faeth's stock tumbles
(14h)
Neuroplastogen biotech Delix raises $100M Series C
(14h)
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
(14h)
#AHA26: Lilly gets another sleep apnea win, this time with obesity pill
(15h)
#AHA26: Marea’s triglyceride candidate could have an edge in diabetic patients
(16h)
Zura reports Phase 2 flop in painful skin disorder; stock nosedives
(16h)
Argenx to acquire Unnatural Products in deal worth up to $1.15B
(19h)
Vir says hepatitis D drug combination succeeds in first pivotal study
(1d)
FDA launches investigation of Novartis’ Zolgensma after cancer cases
(2d)
#AHA26: The similar, surprising Novo and Novartis heart drug failures spelled out
(2d)
Novo’s race to catch Lilly; Q3 earnings recap; and more
(2d)
Church quits role at AI startup Radical, claims ‘sleazy’ behavior stole credit from partner
(3d)
#SITC26: Immunocore reports early data for brenetafusp plus Kimmtrak in uveal melanoma
(3d)
J&J’s Rybrevant nets FDA approval in head and neck cancer
(3d)
BioSpace
BioSpace 2027 Best Places to Work shines light on most admired employers
(1h)
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
(11h)
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
(11h)
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
(12h)
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
(12h)
J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
(14h)
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
(14h)
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
(15h)
Novo’s troubled cardio drug could find niche in less sick patients
(16h)
With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
(1d)
FDA’s new rare disease framework aims to leverage patient voices for better innovation
(1d)
Before GMP: Six manufacturing considerations gene therapy sponsors should address earlier
(1d)
Moderna enjoys stable vaccine sales thanks to global COVID uptake
(3d)
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
(3d)
Agios axes 100-plus R&D roles while awaiting FDA decision
(3d)
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
(3d)
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
(3d)
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
(3d)
Novartis confirms 9 reported cases of tumors linked to spinal muscular atrophy therapy Zolgensma
(4d)
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
(4d)
STAT News
Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drug
(5h)
FDA approves novel Bayer drug to reduce recurrence of stroke
(7h)
Trump administration removes WuXi AppTec from its Chinese military list
(9h)
Bill Ackman’s bold plan to transform brain research
(11h)
Hospitals win the midterms, and Chopping Very Strategically
(12h)
Heart association meeting’s readout is trending ‘neutral’
(13h)
FDA warns GLP-1 drugs carry potential risk of rare eye condition
(14h)
Gene therapy’s long-debated cancer risk materializes
(15h)
Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
(15h)
We’re reading about a Novartis heart drug, BIO fighting a Trump program, and more
(15h)
A new rule to prevent the spread of bioweapons
(17h)
CVS’ split doesn’t fix its fundamental problem
(20h)
Liver experts finally agree on what acute-on-chronic liver failure is
(20h)
Democrats begin asking: How far can we go on health care?
(20h)
AI chatbots aren’t therapists. But can they finally get men to open up?
(20h)
Survival after sudden cardiac arrest didn’t improve despite training bystanders, emergency responders
(1d)
Why the latest heart drug failures should make us all more skeptical of AI hype
(1d)
Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
(2d)
BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
(2d)
Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
(2d)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(10h)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(5d)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(5d)
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers
(2w)
Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows
(4w)
When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides
(1mo)
WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies
(1mo)
The $2.7B Question: How Do We Know If Isomorphic's AI Works?
(1mo)
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line
(1mo)
AI Drug Discovery Startups Raise $526 Million in Two Days
(1mo)
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?
(1mo)
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?
(1mo)
Is “Rescuing Failed Drugs with AI” a Category Now?
(1mo)
Is the Future of AI Drug Discovery Hybrid?
(1mo)
The Bigger Point Beyond Insilico's Aging Research Milestone
(2mo)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(2mo)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(2mo)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(2mo)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(2mo)
Seven HealthTech Trends In Europe To Watch
(4mo)
Drug Channels
BlinkRx Insights: Clarifying the Mystery around “DTP”
(3d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(4d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(6d)
Biopharma’s AI Fork in the Road
(1w)
"How Do I Know I'm Not Just Giving Money Away?" The Question Every Market Access Leader Is Asking
(1w)
Drug Channels News Roundup, October 2026: Part D’s Hidden Cost Sharing Gap, 340B’s $244 Billion Footprint, The Net Price Rebate Model, Cigna’s Wholesale Push, and Four Ways to Bag a Drug
(2w)
Copay + GTN Revenue Protection = Better Together
(2w)
Alternative PBM Satisfaction Declined in 2026, Shrinking the Advantage Over the Big Three PBMs
(3w)
Informa's Trade and Channel Strategies
(3w)
10 Crucial Trends Facing U.S. Drug Wholesalers in 2026 and Beyond
(4w)
NOW AVAILABLE: DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(4w)
Transparency is No Longer a Compliance Issue
(1mo)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)
(1mo)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges (rerun)
(1mo)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains (rerun)
(1mo)
Informa’s PBM Contracting Summit
(1mo)
Patient Support Strategy by Lifecycle Stage: Launch, Growth, Maturity, and Loss of Exclusivity
(1mo)
Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence from Copay Cards, Negative Part D Premiums, and Drug Channel Dating Profiles
(1mo)
Why GoodRx Is Built for the AI-Driven Patient Journey
(1mo)
The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show
(1mo)
European Biotechnology Magazine
Immunocore doubles up on T-cell engagers in eye cancer
(13h)
argenx buys macrocycle partner Unnatural Products for up to $1.15 billion
(22h)
CDMO: How to find a reliable partner
(1d)
When genetic medicine enters the inner ear
(1d)
Turn bioprocess data into timely, transferable process control
(3d)
Spinal muscular atrophy: Tumors reported following Novartis gene therapy
(3d)
Oculis taps Roche veteran after setback; ARTHEx brings in Azafaros’ CMO; CRISPR recruits Orna’s former CTO
(3d)
Dutch biotech Anaheim launches with €40M to develop pseudogout treatment
(3d)
Boehringer secures six Chinese cancer programs in deal worth up to $7B
(4d)
BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver
(4d)
Bayer closes the gap with Boehringer in China’s lung cancer race
(4d)
T-Therapeutics raises $133M to bring TCR bispecifics into clinic
(4d)
Oxford spinout Alethio raises $90M Series A for chronic blood cancer trials
(5d)
Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback
(6d)
The CDMO partner for next-gen medicine
(6d)
Novartis ends BioArctic brain-delivery deal worth up to $802M
(6d)
Danish BioInnovation Institute builds a bridge to Germany
(6d)
AstraZeneca targets $1.5B in savings; Ayrmid bids for Karyopharm; Sanofi pays $125M to Novavax
(6d)
Fresenius turns to WuXi to add up to 37 biosimilars to its pipeline
(1w)
Where Life Science Scales in Basel
(1w)
Drug Hunter
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(14h)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(15h)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(3d)
RG6182
(4d)
A Deep Dive into INN Proposed List 135 Part 2 (M–Z)
(5d)
A Deep Dive into INN Proposed List 135 Part 1 (A–L)
(6d)
Two Fluorines, One Carbon, Many Possibilities
(1w)
September 2026 Patent Gazette
(1w)
September 2026
(2w)
pamiparib
(2w)
Will Lowering Lp(a) Levels Reduce Cardiovascular Events?
(2w)
Leveraging Platform Innovation to Tackle Tough Targets
(2w)
PF-07976016
(2w)
CNS Cheat Sheet
(2w)
ibrutinib
(3w)
camlipixant
(3w)
zilurgisertib
(3w)
The Sulfoximine Paradox: Understanding the Unique Physicochemical Properties of Secondary Sulfonamide Bioisosteres
(3w)
NVP-KFA115
(3w)
UCB6492
(4w)
Labiotech.EU
Zooming out from ovaries: how has renaming PMOS changed lives?
(3d)
How to turn a BIO-Europe meeting into a lasting partnership
(3d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(5d)
The biggest biotech funding rounds in October 2026
(5d)
Top biotech deals in October 2026
(6d)
Why global expansion is changing the shape of the ATMP supply chain
(6d)
Teva’s pipeline in 2027: Can it sustain its transformation?
(1w)
ESMO 2026: readouts and highlights at the oncology summit
(1w)
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
(1w)
New idiopathic pulmonary fibrosis drugs on the way
(2w)
TROP2 ADCs: The race to capture the next oncology opportunity
(2w)
13 of the best biotech incubators hatching startups in Europe
(2w)
The stranded asset problem in microbial custom manufacturing
(2w)
Novavax’s new strategy: Betting its future on partnerships
(2w)
Beyond dilation: six biotechs advancing pulmonary hypertension therapies
(2w)
GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
(2w)
Oncology biotech news: key moves to watch in October 2026
(3w)
Shifting the standard: myopia companies to look out for
(3w)
Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035
(3w)
Great gene editing. Now prove it without overcomplicating the analysis
(3w)
Bio IT World
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(23m)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(3d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(5d)
Quantifying the Average Human Genome
(1w)
Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing
(2w)
Follow the Money: OMass Raises Series C, Pathos AI Drug Development, Owkin Alums Launch Rivercell
(2w)
ParkourSC Acquires Quartic, PacBio Partners with Verily, CAS Data Arrives in Microsoft Copilot
(2w)
Innovating at Speed in an Underrated Drug-Making Process
(3w)
Inside the ‘Public Library of Blueprints’: How the ASAP Discovery Consortium Turned Open Science Into an Antiviral Pipeline
(3w)
New Pipeline Reveals RNA Fusions Formed During Inflammation, Opens New Frontier in Biology
(3w)
From Hard Drives to Self-Service: How ASU and Starfish Storage Unlocked 25 Years of Indigenous Health Data
(4w)
Eric Schadt on Truly Precise Medicine and AI in Pharma and Healthcare
(4w)
2027 Innovative Practices Awards Call for Entries
(4w)
Is AI The Key To Earlier Detection Of Pharmaceutical Safety Risks?
(1mo)
MIT Microscope Captures Whole-Brain Voltage Activity at Millisecond Speed, Opening New Doors for Neurotech and Drug Discovery
(1mo)
Record-Setting Brain Organoid Holds Vast Medical Potential
(1mo)
Follow the Money: Gene Therapy, Pediatric Brain Cancer CAR T, Thyroid Eye Disease
(1mo)
Sanofi Hands 20 Mature Medicines to Cheplapharm, NVIDIA Backs Verily, Roche Inks $1B Bispecifics Deal with Dualitas
(1mo)
AI-Powered Diagnostic Advances Organ Transplant Surveillance
(1mo)
A Field in Transition: T Cell Engagers
(1mo)
GEN News
Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research
(6h)
How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome
(9h)
Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests
(16h)
New AI Models Are Turbo-Charging Protein Design
(16h)
Therapeutic Immune Manipulation
(16h)
Formulation Development Roundup
(16h)
StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate
(1d)
The Aging Proteome: Clocks, Cohorts, and Clinical Trials
(3d)
Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma
(3d)
ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals
(3d)
Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics
(3d)
Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors
(4d)
Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical
(4d)
Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests
(4d)
Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion
(4d)
Revealing the Chemistry Around Us Through Mass Spectrometry
(4d)
Tissue Engineering Takes Shape
(4d)
Beyond Conventional CRISPR
(4d)
Oral Sleep Apnea Therapy Poised to Expand Treatment Options
(4d)
Beyond the Payload
(4d)
Cure Today
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
(8h)
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
(10h)
Rural Lung Cancer: Only 36% of Medicare Patients Had Gene Testing
(14h)
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
(16h)
Nearly Half of Cancer Survivors Report Recent Alcohol Use
(2d)
Hot Flash Drug Works at Any Point in Breast Cancer Hormone Therapy
(2d)
Glioblastoma Genomic Testing: What Patients Should Ask
(3d)
How Patients With Breast Cancer Can Catch Lymphedema Before Swelling Starts
(3d)
Survivor Guilt After a Double Mastectomy for DCIS Breast Cancer
(3d)
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
(3d)
Enhertu Before Surgery Falls Short in HER2-Low Early Breast Cancer
(3d)
Pancreatic Cancer and Enzyme Pills: Why They Matter at Every Meal
(3d)
Life After Chemotherapy: A Patient With Pancreatic Cancer Describes Daily Life on Rasonque
(4d)
What Is a Whipple Procedure? Pancreatic Cancer Surgery Explained
(4d)
5 Lung Cancer Immunotherapy Side Effects and How to Manage Them
(4d)
Rasonque for Pancreatic Cancer: Patients Discuss Benefits, Risks and Access
(4d)
Sac-TMT Plus Keytruda Improves Outcomes in PD-L1-Negative Lung Cancer
(5d)
After Breast Cancer, Thanksgiving Is No Longer Just One Day
(5d)
Palliative Care vs. Hospice With Cancer: Your Questions Answered
(5d)
App Provides Educational Resources for Patients With Urologic Cancers
(5d)
Contract Pharma
Spruce Bio Spins CAH Program Off into New Subsidiary Adrenyx
(8h)
Pluri CDMO Business Adds Two ISO Certifications
(14h)
Charles River to Acquire Frontage’s Bioanalysis, DPMK Businesses
(15h)
Pierre Fabre, XtalPi Partner to Advance AI-Driven Drug Discovery
(15h)
Centrix Appoints Nathalie Huther as SVP, Business Development & Commercial
(16h)
Hovione Discusses Spray Drying Expansions in US and Europe
(3d)
Chai Discovery, Roche to Collaborate on AI Drug Discovery
(3d)
Can AI Solve Pharmacovigilance’s Evidence Bottleneck?
(3d)
FDA Approves J&J’s Rybrevant Faspro with Halozyme’s Enhanze for Head and Neck Cancer
(3d)
Lotte Biologics CEO on Alvotech Deal, Manufacturing Expansion and Building a New CDMO Model
(3d)
The Friday Brief for November 6, 2026: Plenty of Partnerships
(3d)
Bio-Thera Wins China Approval for First Golimumab Biosimilar
(3d)
Phillips Medisize to Acquire Complete Footprint of Chippenham Site
(4d)
PharmAla Engages Corealis for GMP Manufacturing of Candidate for Clinical Supply
(4d)
ACG Taps Philippe Azzi as Sales Director, North America
(4d)
Thermo Fisher Launches Value-Priced AmpSure qPCR Master Mixes
(4d)
Concept Life Sciences Appoints Dean Bornilla as Chief Commercial Officer
(4d)
Live from CPHI Milan: Q&A with Jim Donovan of Pfizer CentreOne
(5d)
Agilent Completes $240M Proscia Acquisition
(5d)
Minghui, ASKA Agree to License and Commercialize TED Treatment in Japan
(5d)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1mo)
Study highlights advance in influenza protection for older adults
(1mo)
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
(1mo)
Teitur reports positive early data for Parkinson’s peptide TT‑P34
(1mo)
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
(1mo)
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
(2mo)
Livdelzi accepted in Scotland for treatment of PBC
(2mo)
Jemperli accepted for priority review by US FDA
(2mo)
Carterra supports AI‑designed protein study with HT-SPR platforms
(2mo)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(2mo)
Avulux gains FDA authorisation for migraine light‑sensitivity lens
(2mo)
Leqembi Iqlik launches in US for early Alzheimer’s
(2mo)
Lundbeck gains EU orphan status for anti‑ACTH antibody
(2mo)
AC Immune reports positive phase 1 data for ACI‑19764
(2mo)
VarmX begins global phase 3 trial of VMX C001
(2mo)
VarmX begins global phase 3 trial for VMX C001
(2mo)
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
(2mo)
Medcity News
Startup Supporting Caregivers Raises $3.5M in Seed Funding
(6h)
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
(8h)
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
(8h)
Simulation-Guided Clinical Trials: Is EU Law Ready?
(15h)
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
(18h)
What’s Driving the Consumerization of Healthcare?
(1d)
Missing the Point: Isolation Alone Will Not Build AI Safety
(1d)
Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer
(3d)
Experian Health Survey: Providers Struggle Amid Increasing Claim Denials
(3d)
The Big Challenge for AI in Healthcare Comes After Approval
(3d)
Why Physician Leadership Is More Important Than Ever
(3d)
Myths of Customer Discovery
(3d)
Debunked Episode 31: CVS Health Restructure, AI ROI Report Findings, FTC Warning Letters
(3d)
How Can Payers Fit Into the Consumer Health Era?
(4d)
Do We Have a Choice But to Ensure the Success of VBC? Part 1
(4d)
Why the Wealth of Data From Wearables Are Important for Consumers and Clinicians
(4d)
AI Didn’t Reduce Clinician Burden — It Just Moved It
(4d)
The Dangerous Illusion of the “Two-Week AI Expert”: A Call to Action Against Superficial Medical Education
(4d)
The AI-Native Clinician Is Already Here. Medical Education and Health Systems Need to Catch Up.
(4d)
When Medicaid’s Data Can’t Verify Eligibility, Members Shouldn’t Lose Coverage
(4d)
Chemical & Engineering News
Comment: To NOBCChE, community is everything
(5h)
Chemistry in Pictures: Golden tears
(10h)
Mitsui Chemicals will acquire JSR in electronic materials push
(11h)
Purple bacteria transform waste into valuable antioxidant
(13h)
ACS expands public policy fellowships
(14h)
Comment: Creating pathways to success through Project SEED
(16h)
Uncovered: Plastic pyrolysis
(17h)
C&EN Chemwords, Nov. 9
(17h)
‘Journal of Physical Chemistry Letters’ names next editor in chief
(3d)
Using old wind turbine blades to make new ones
(3d)
Chemist wins bronze at world fencing championships
(3d)
C&EN weekly chemistry news quiz, Nov. 6
(3d)
Magid Abou-Gharbia wins 2026 John Scott Award
(4d)
FDA updates infant formula nutrient standards but omits botulism threat
(4d)
Urban firestorms pose unique air quality risks to residents
(4d)
Wheat kernels analyzed for better bread
(4d)
Policy Watch: EPA inspector general to audit agency’s AI use
(4d)
Archaeologists find direct evidence of cannabis use from 2,800 years ago
(4d)
How the CIA tried to use chemistry to kill Castro—and why it failed
(4d)
How cellophane bees make a plastic that doesn’t pile up
(4d)
The Pharma Letter
Pierre Fabre and XtalPi ink discovery AI-driven collaboration
(13h)
Adneuris files cebranopadol NDA for acute pain, pitching lower abuse potential than oxycodone
(13h)
Almirall nine-month sales up 8.3% as Ebglyss surges 75% and EBITDA climbs 22.7%
(16h)
Russia to sharply increase production of human papillomavirus vaccines
(16h)
Avanzanite builds EU commercial operation by securing Zemcelpro rights
(17h)
Pelacarsen cuts Lp(a) by 78% but not cardiovascular events in Phase III HORIZON trial
(17h)
Amgen’s Repatha lowers risk of heart attacks by 20%
(18h)
Amgen’s Repatha lowers risk of heart attacks by 20%
(18h)
SRTD Biotech raises a 31.5 million euros to develop mRNA therapeutics
(18h)
How hep C went from an $84,000 cure to mass treatment
(20h)
J&J's icotrokinra meets Phase III goal in psoriatic arthritis
(20h)
Regulatory round-up: 9 November 2026
(20h)
Astellas exec calls for more coordinated EU drug access rules
(20h)
Novo releases real-world studies of Wegovy for MASH
(21h)
Oncology care in Greece
(21h)
The week in pharma: action reaction and insight – week to November 6, 2026
(1d)
The week in pharma: action reaction and insight – week to November 6, 2026
(1d)
Pharming wins MHRA approval to expand Joenja indication
(2d)
Positive new data for twice-yearly lenacapavir in HIV prevention
(2d)
Novo pulls out of accord with Korro Bio
(2d)
Targeted Oncology
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
(8h)
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
(10h)
Dr Iyer on Digitizing NCCN Guidelines for AI at the Point of Care
(11h)
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
(13h)
Benzopyran-Based Small Molecule Granted FDA Orphan Drug Status in AML
(14h)
Pembrolizumab Plus SBRT Fails to Improve EFS in Unresected Early-Stage NSCLC
(17h)
Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETs
(1d)
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
(1d)
Real-World Data Reveal Risk Factors for Myeloid Neoplasm After Lutetium Lu 177 Dotatate
(1d)
Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine Cancers
(2d)
PROs Capture What Survival Data Miss in Neuroendocrine Neoplasms
(2d)
Dr Trikalinos on Cabozantinib in Functional and Nonfunctional NETs
(2d)
Liver Transplant Offers Durable Survival in NET Liver Metastases Despite Recurrence
(2d)
Dr Lewis on Cabozantinib and Time Toxicity in Neuroendocrine Tumors
(2d)
Endovascular Options Offer Relief for Venous Occlusion in Select Patients With NETs
(2d)
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
(2d)
Oncolytic Virus SVV-001 Plus Ipi/Nivo Is Safe in High-Grade Neuroendocrine Cancers
(2d)
Dr Sorbye on Separating NET G3 From NEC Before Choosing Therapy
(2d)
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
(2d)
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
(3d)
MedWatch
Ambu board seeks sharp increase in executive bonus caps
(17h)
Demant goes on offensive with US veterans: “We aim to steadily expand our position”
(17h)
Trustee to seek disqualification of former Audientes management
(19h)
Sandoz launches Ozempic copy in Brazil
(20h)
Wegovy improves liver markers in MASH patients without obesity
(21h)
Coloplast nominates Lundbeck CEO to its board
(21h)
Novo Nordisk releases real-world data on semaglutide in fatty liver disease
(22h)
Market turmoil threatens Leo Pharma’s planned IPO, Berlingske reports
(22h)
EU clears GN Hearing sale to Amplifon, bringing billion-krone payout closer
(3d)
Eli Lilly teams up with Hims & Hers on obesity drugs
(3d)
Copenhagen medtech company loses longtime CEO in the middle of global expansion
(3d)
Russia still spends more than half its drug budget on imports
(3d)
Genmab CFO backs analysts’ 2027 cost estimates
(3d)
Ambu CEO welcomes EU curbs on Chinese rivals as a major competitive advantage
(3d)
Gubra narrows CRO outlook but posts second-best quarter on record
(4d)
Ambu delays key margin target to speed up push for endoscope sales
(4d)
Demant CEO focuses on cybersecurity after new WSA attack: “I wish them all the best”
(4d)
Investor sees benefit in Novo Nordisk bringing in outside CFO: “Novo can become a little complacent”
(4d)
Analyst warns Zealand Pharma’s next survodutide study may disappoint on tolerability again
(4d)
GN plans DKK 4bn in share buybacks after hearing aid sale
(4d)
In The Pipeline
Jon Clardy, 1943-2026
(9h)
Antimicrobial Peptides for Fun (?) and Profit (?)
(4d)
The Morning After the Midterms
(5d)
Taming Photochemistry
(6d)
Chemotherapy Actually Helps Immunotherapy in Cancer
(1w)
Messing Around With the Warburg Effect
(2w)
Lipidation and Its Discontents
(2w)
What Does It Mean to "Know Medicinal Chemistry"?
(2w)
The Merck/Moderna Results
(2w)
Elevenostat: Don't Believe the Label
(3w)
The Case of the Should-Be-Missing Proteins
(3w)
Two Weeks to Go
(3w)
Sulfur, Right There All Along
(3w)
How LLMs Deal With Fraudulent Papers
(4w)
Accelerated Reactions in an Electric Field
(4w)
The 2026 Nobel Prize in Chemistry: Chirality Abounds
(4w)
Time Off
(1mo)
Hold Up a Minute
(1mo)
Now That's An Impurity Story
(1mo)
AI Help for Biological or Chemical Weapons
(1mo)
Pharmaphorum
Amazon puts $100m into global health drive
(16h)
MHRA grants Innovation Passports to three novel drugs
(17h)
argenx agrees Unnatural takeover deal worth up to $1.15bn
(18h)
Moderna to relocate its UK HQ to London's Tribeca
(19h)
Novartis' pelacarsen fail raises questions for other drugs
(20h)
Lilly partners with Hims & Hers on obesity drug sales
(3d)
Inflammation-focused Rezera sets terms for IPO
(3d)
Moderna, Oxford Uni Ebola jabs backed for pivotal testing
(3d)
UK pilots shorter NICE appraisal for new medicines
(3d)
J&J's Rybrevant moves beyond lung cancer with new approval
(3d)
J&J's Rybrevant Faspro moves beyond lung cancer with FDA nod
(3d)
UK backs startup Potential Sciences' AI-powered drug hunt
(4d)
UK backs start-up Potential Sciences' AI-powered drug hunt
(4d)
Bayer's Hyrnuo moves first-line for lung cancer in China
(4d)
UK biotechs T-Therapeutics and Alethio score big financings
(4d)
NICE backs Keytruda/Padcev combo for bladder cancer
(4d)
Boehringer forges $7bn alliance with China's SBP Group
(5d)
Oral Wegovy bolsters Novo in Q3
(5d)
UK women's health firm Theramex sold for around £2.2bn
(5d)
AbbVie invests £120m in UK expansion
(5d)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(1w)
Why we need to rethink childhood cancer treatments
(1w)
Q3 UK biotech VC heads for record year thanks to megadeals
(1w)
Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers
(1w)
New webinar: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
Partnership advances AI-driven R&D collaboration
(2w)
The three generations of obesity medicines
(2w)
Webinar: Exploring warm PDX benefits and onsite expertise
(2w)
Beyond the model: Exploring warm PDX benefits and onsite expertise
(2w)
ScionxBio collaborates to develop long-acting xRNA therapeutics
(2w)
Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3
(2w)
TILT reports encouraging data at ESMO
(2w)
New eBook: Next-generation neuroscience drug discovery
(2w)
Next week: DDW’s Drug Discovery Innovators and Investors (DDII) conference
(2w)
UK Budget promises £70m for life sciences and lifts VAT on free medicines
(2w)
Read the Guide: Predict cardiac safety early
(2w)
Next-generation neuroscience drug discovery
(2w)
Webinar: From PK/PD and biomarkers to decision-making
(2w)
Trial data presented at ESMO support cancer microbiome therapy
(2w)
Designing multiomics studies to capture biological response
(2w)
HIT Consultant
AWS Launches $100M Health Impact Initiative to Scale Agentic and Cloud Tech in Underserved Global Care
(13h)
M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics
(14h)
Reclaiming $44.9B in Hospital Uncompensated Care via Automated Upfront Eligibility
(15h)
CLEAR Launches Epic Toolbox Integrations for EpicCare Link and DEA-Compliant EPCS
(16h)
SEARHC Joins Mayo Clinic Care Network to Bridge Specialist Tele-Informatics Across Southeast Alaska
(16h)
GDIT, IHS, and Oracle Health Deploy PATH EHR as the First Cloud-Native Federal Health System
(16h)
Why Patient Access Is Healthcare’s Highest-Leverage Growth Lever
(1d)
Do Patients Need to Understand AI Before They Can Trust It?
(3d)
M&A: Ellipsis Health Acquires Kouper Health to Unify Vocal Empathy with Native EHR Navigation
(3d)
FinThrive Appoints Ex-Optum Executive Sam Meckey as CEO to Accelerate End-to-End RCM AI Orchestration
(3d)
Altera Digital Health Files WARN Notice to Cut 133 Melville Roles as Client Contracts Expire
(3d)
Why Healthcare Can’t Skip Steps on the Way to Conversational AI
(4d)
Fairview Health Services Selects Layer Health to Automate Enterprise Clinical Registry Abstraction
(4d)
CMS Finalizes CY 2027 Physician Fee Schedule to Accelerate Value-Based Prevention and Curb Duplicate Billing
(4d)
Wolters Kluwer Survey Exposes the Chasm Between Enterprise AI Acceleration and Consumer Drug Safety Trust
(4d)
HHS Welcomes VA and Defense Health to TEFCA to Unify Care for Millions of Veterans and Service Members
(4d)
Roche Partners with Chai Discovery to Deploy Chai-3 Across Global Therapeutic Pipelines
(4d)
Former Salesforce CMO Dr. Joshua Newman Appointed Chief Medical Officer at Navina
(4d)
Consumer AI Is Healthcare’s New Front Door. Who’s Deciding What Happens There?
(4d)
Why the AMA’s AI Liability Policy Shifts Risk to Health System Data Access Logs
(5d)
Insights: Pink Sheet
US FDA Defines Risk-Based Potency Approach To Cell and Gene Therapy
(2h)
Korea Streamlines Review Of Digital Convergence Combos
(3h)
US FDA Probes Tumor Risk With Novartis’ Zolgensma And Itvisma After Gene Integration Reports
(5h)
GLP-1 Class Warning On Rare Eye Condition Driven By US FDA Meta-Analysis, Sentinel Study
(6h)
EU Risks ‘Completely Screwing Up’ Pharma Sandboxes, Academic Warns
(16h)
Recruitment To Industry Trials Falls For Fifth Year In UK Despite Faster Approvals
(16h)
Ad/Promo: Multiple US FDA Advisory Comment Requests OK, But Know Their Limits
(3d)
CMS Retains ‘Value Of 12’ For One-Time Therapies In Medicare Negotiation Despite Pushback
(3d)
US FDA Biologics Center Joins Hiring Binge, Posts First Net Gain Since Pre-Trump Administration
(3d)
Pink Sheet Podcast: How Will FDA And Rx Industry Navigate Aftermath Of Midterm’s Blue Wave?
(3d)
UK Flexibility On Non-OECD Data Could Widen Trial Opportunities
(3d)
EU Pharma Sandbox Plans Risk National Regulatory Pushback, EFPIA Warns
(3d)
MFN: EU Anti-Coercion Instrument Could Counter US Drug Pricing Threats
(3d)
New Korea Patient Experience Framework Recognizes ‘Key Stakeholders’
(4d)
Telehealth Company’s Personalized ‘Tirzepatide+’ Claims Ruled Unsupported In Lilly Challenge
(4d)
CMS Finalizes Combo Drug Policy As Botox Ruling Clouds Negotiation Authority
(4d)
US FDA Creates Cross-Product Supply Chain Council In New Office Of National Health Security
(4d)
MFN Revisions, Codification Unlikely In Divided US Government, Pfizer’s Bourla Suggests
(4d)
Industry Fears Making EU Sandboxes ‘Too Exceptional’ Will Backfire On Innovation
(4d)
Quotable: Top Experts On Policy Hot Topics
(4d)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(2d)
Standardization, not customization: A site-CRO perspective on trial quality
(8h)
Survey finds women are willing to join trials, yet rarely invited
(11h)
Argenx buys into macrocyclic peptides with $1.15bn UNP deal
(15h)
Pharma urged to build pricing resilience
(15h)
Small patients, big breakthrough: Using peptides to treat hypoxic brain injuries in preterm babies
(17h)
Medicare Part D premiums, caps climb in 2027 plans
(3d)
Novartis under scrutiny as nine tumor cases reported in Zolgensma SMA patients
(3d)
Indian CDMO Shilpa commits to $50M expansion in peptide manufacturing
(3d)
When speed to market outpaces readiness to lead
(3d)
Nonprofit gene therapy for Wiskott-Aldrich syndrome lands on US shores
(4d)
T-Therapeutics nets $133m to push T cell engagers toward the clinic
(4d)
GoodRx takes employer direct GLP-1 program nationwide to curb rising employee drug costs
(4d)
Nxera's gut-targeted molecule nets $1.47bn from AbbVie
(4d)
Alethio banks $90m to target rare blood disorder
(4d)
Boehringer Ingelheim, Microsoft to develop AI ‘digital patients twins’ for trials
(5d)
Rhythm Pharmaceuticals changes its tune with LG Chem on obesity drug
(5d)
GSK exec shares framework to refresh mature brands marketing
(5d)
HHS greenlights sale of six unapproved peptides despite FDA guidance
(5d)
bit.bio lands $25m Series D as human cell demand hits record highs
(5d)
BioCentury
China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast
(3d)
Post-election pricing outlook: stormy with a chance of compromise
(3d)
Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report
(3d)
Brinsupri, Rasonque extend biotech's launch momentum
(3d)
SITC 2026: Engineering immune responses inside tumors
(4d)
With $600M fund, Formation Bio puts a financing twist on hub-and-spoke model
(4d)
Alethio: A mutation-agnostic approach to essential thrombocythemia
(4d)
Nisa Leung’s Aulis Capital closes $200M debut fund: Venture Report
(4d)
Innovation Radar: New clues to targeting Alzheimer’s microglia
(5d)
Building biology’s missing datasets to train AI models
(5d)
FDA approves first DNA plasmid immunotherapy; NME tally reaches 47
(5d)
Lilly extends GLP-1 lead — except in orals
(5d)
With Vidya acquisition, Gujrathi takes chair role at Processa
(6d)
Caspian: Regenerating beta cells with a menin inhibitor
(6d)
FDA needs a roadmap for disease-agnostic drug development — a Perspective
(6d)
Radiopharma venture money moves toward alpha emitters
(6d)
ESMO’s first-in-human signals, Auchincloss’ proposal & COINS reaction — a BioCentury podcast
(1w)
Astellas takes option on Audax’s IL-12 program: Deals Report
(1w)
Missed endpoints, futility findings drive string of CNS discontinuations
(1w)
Pharma’s U.S. contributions favor incumbents
(1w)
SCRIP
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
(1h)
Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs
(7h)
ACR 2026: A Tale Of Three Cell Therapies
(8h)
Argenx Buys Unnatural Products, Gaining Macrocyclic Peptide Discovery Platform
(8h)
BIO-Europe: Wise Words From Industry Vets Levin And Moses
(14h)
J&J’s Prostate Cancer Combo Shows Promise, As Phase III Proceeds
(16h)
Scrip’s Five Must-Know Things: Madrigal’s MASH Whistleblower, Lilly, Sanofi Hunt Deals
(1d)
AASLD 2026: Madrigal Plans New Phase III Study In Cirrhotic MASH
(3d)
Market Snapshot: After Mimrylo, What’s Next For Myeloproliferative Neoplasms?
(3d)
J&J’s Rybrevant Faspro Should See Few Challenges In Head And Neck Uptake
(3d)
Glenmark Leans On AbbVie Myeloma Bet As BioCryst Hands Back STAR-0310
(3d)
ANI To Expand Its Rare Disease Portfolio With Egetis Takeout
(4d)
Cloudbreak To Take Positive Pterygium Data To US FDA
(4d)
China Partnering Pioneer Huyabio Ready To File Melanoma Therapy
(4d)
Revolution’s Rasonque Sets New Benchmark For Oncology Launch Sales, Scrip Analysis Shows
(4d)
AASLD 2026: Gilead Eyes Wider Livdelzi Use As Phase III Data Bolster PBC Expansion Plans
(4d)
Scrip’s Guide To November: Novel Anticancer Approvals Await
(4d)
UK’s Alethio Banks $90m In Bid To Transform ET Treatment
(4d)
Zydus Pulls Plug On Saroglitazar’s US MASH Plans, But Biomedtracker Sees 99% PBC Approval Odds
(4d)
Astellas Optimistic On Padcev Growth But Braces For Xtandi IRA Impact
(5d)